Results 41 to 50 of about 28,066 (219)

PCSK9 Inhibitor Use and Outcomes Using Concomitant Lipid-Lowering Therapies in the Veterans Health Administration

American Journal of Medicine Open, 2023
Background: Real-world data on use of PCSK9 inhibitors (PCSK9-Is), with or without statins and/or ezetimibe, and associated outcomes, can inform more effective prescribing.
Jessica Eloso, Asma Awad, Xinhua Zhao, Francesca E. Cunningham, Rongping Zhang, Diane Dong, Cathy Kelley, Peter A. Glassman, Sherrie L. Aspinall   +8 more
doaj   +1 more source

PCSK9 Activity Is Potentiated Through HDL Binding [PDF]

, 2021
RationaleProprotein convertase subtilisin/kexin type 9 (PCSK9) circulates in a free and lipoprotein-bound form, yet the functional consequence of the association between PCSK9 and high-density lipoprotein (HDL) remains unexplored.ObjectiveThis study ...
Bodo Levkau, Kiechl, Stefan, Theofilatos, Konstantinos, Levkau, Bodo, Wendy L. Hall, Notdurfter, Marlene, Marlene Notdurfter, Sarah E. Berry, Ruifang Lu, Paulweber, Bernhard, Hall, Wendy L, Sean A. Burnap, Gerd Heusch, Pechlaner, Raimund, Heusch, Gerd, Mayr, Manuel, Carlos Fernández-Hernando, Kaloyan Takov, Katherine Sattler, Konstantinos Theofilatos, Gregorio Rungger, Fernández-Hernando, Carlos, Willeit, Johann, Burnap, Sean A, Sattler, Katherine, Elisa Duregotti, Takov, Kaloyan, Sotirios Tsimikas, Lu, Ruifang, Takov, Kaloyan; id_orcid, Mayr, Manuel; id_orcid, Duregotti, Elisa, Stefan Kiechl, Tsimikas, Sotirios, Bernhard Paulweber, Raimund Pechlaner, Johann Willeit, Berry, Sarah E, Manuel Mayr, Rungger, Gregorio, Hall, Wendy Louise; id_orcid   +40 more
core   +1 more source

Low levels of PCSK9 are associated with remission in patients with rheumatoid arthritis treated with anti-TNF-α: potential underlying mechanisms

Arthritis Research & Therapy, 2021
Background Proprotein convertase subtilisin kexin 9 (PCSK9) targets the LDL-receptor (LDLR) which raises LDL-levels. In addition, PCSK9 has proinflammatory immunological effects.
Johan Frostegård, Sabbir Ahmed, Ingiäld Hafström, Sofia Ajeganova, Mizanur Rahman   +4 more
doaj   +1 more source

PCSK9: A Key Target for the Treatment of Cardiovascular Disease (CVD) [PDF]

Advanced Pharmaceutical Bulletin, 2020
Proprotein convertase subtilisin/kexin type 9 (PCSK9), as a vital modulator of low-density lipoprotein cholesterol (LDL-C) , is raised in hepatocytes and released into plasma where it binds to LDL receptors (LDLR), leading to their cleavage.
Saeideh Sobati, Amir Shakouri, Mahdi Edalati, Daryoush Mohammadnejad, Reza Parvan, Javad Masoumi, Jalal Abdolalizadeh   +6 more
doaj   +1 more source

Allosteric Modulation of PCSK9-LDLR Interaction: Can Structureless Loops be Drug Targets? [PDF]

, 2022
While most of the drugs available in the market are competitive inhibitors, there is a rapidly growing interest in development of allosteric drugs, particularly to inhibit protein-protein interactions (PPI) with large interaction surface area.
Suman, Chakrabarty, Zacharia , Shah, Salim , Shah, Krishnendu , Sinha, Ipsita, Basu   +4 more
core   +2 more sources

Elevated circulating PCSK9 level is associated with 28-day mortality in patients with sepsis: a prospective cohort study

BMC Emergency Medicine, 2023
Objectives Pro-protein convertase subtilisin/kexin 9 (PCSK9) decreases the clearance of the pathogenic lipids, supporting the potential role of PCSK9 in the prognosis of sepsis.
Yuanlu Shu, Ziwei Deng, Ye Deng, Jianliang Zhou, Jin Wang, Zhenxing Duan, Tao Jiang, Xiang Zhao, Zhihua Shi, Chengfeng Qiu   +9 more
doaj   +1 more source

Increased serum PCSK9 levels are associated with renal function impairment in patients with type 2 diabetes mellitus

Renal Failure, 2023
Purpose The purpose of this study was to investigate the association between serum proprotein convertase subtilisin/kexin type 9 (PCSK9) levels and renal function impairment in type 2 diabetes mellitus (T2DM) patients.Methods PCSK9 levels were measured ...
Zhicai Feng, Xiangyu Liao, Hao Zhang, Juan Peng, Zhijun Huang, Bin Yi   +5 more
doaj   +1 more source

Circulating Rather Than Intestinal PCSK9 (Proprotein Convertase Subtilisin Kexin Type 9) Regulates Postprandial Lipemia in Mice

, 2020
International audienceObjective: Increased postprandial lipemia (PPL) is an independent risk factor for atherosclerotic cardiovascular diseases. PCSK9 (Proprotein convertase subtilisin kexin type 9) is an endogenous inhibitor of the LDLR (low-density ...
Nabil Seidah, Lucie Arnaud, Ayer, Audrey, Prieur, Xavier, Arnaud, Lucie, Bertrand Cariou, Garçon, Damien, Prat, Annik, Annik Prat, Dijk, Wieneke, Cédric Le May, Anna Roubtsova, Damien Garçon, François Moreau, Seidah, Nabil, Cariou, Bertrand, Audrey Ayer, Moreau, François, Roubtsova, Anna, Wieneke Dijk, Xavier Prieur, Le May, Cedric   +21 more
core   +1 more source

PCSK9 deficiency alters brain lipid composition without affecting brain development and function

Frontiers in Molecular Neuroscience, 2023
PCSK9 induces lysosomal degradation of the low-density lipoprotein (LDL) receptor (LDLR) in the liver, hereby preventing removal of LDL cholesterol from the circulation.
Angela Pärn, Ditte Olsen, Jürgen Tuvikene, Jürgen Tuvikene, Mathias Kaas, Ekaterina Borisova, Ekaterina Borisova, Mesut Bilgin, Mie Elhauge, Joachim Vilstrup, Joachim Vilstrup, Peder Madsen, Peder Madsen, Mateusz C. Ambrozkiewicz, Roman U. Goz, Tõnis Timmusk, Tõnis Timmusk, Victor Tarabykin, Victor Tarabykin, Camilla Gustafsen, Camilla Gustafsen, Simon Glerup, Simon Glerup   +22 more
doaj   +1 more source

Role of PCSK9 on vascular calcification: study of an uremic mouse model

, 2022
reservedLa patologia cardiovascolare è la prima causa di morbilità e mortalità nei pazienti affetti da malattia renale cronica (CKD). Una funzione renale compromessa comporta un’alterazione del profilo lipidico e in associazione con elevati livelli ...
RIZZATO, MARTINA
core